Indivior Pharmaceuticals, Inc. Estimated Litigation Liability, Noncurrent
Indivior Pharmaceuticals, Inc. (INDV) had Estimated Litigation Liability, Noncurrent of $42.00 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:LitigationReserveNoncurrent · last filed 2026-08-03
- 2026-06-30: Estimated Litigation Liability, Noncurrent $42.00M.
- 2026-03-31: Estimated Litigation Liability, Noncurrent $41.00M.
- 2025-12-31: Estimated Litigation Liability, Noncurrent $52.00M.
- 2025-09-30: Estimated Litigation Liability, Noncurrent $300.00M.
| Period end | Estimated Litigation Liability, Noncurrent |
|---|---|
| 2026-06-30 | $42.00M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $41.00M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $52.00M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $300.00M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $299.00M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $297.00M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $365.00M 10-K · filed 2026-02-26 |
| 2023-12-31 | $359.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |